Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematological malignancies.The current dominant manufacturing approach for CAR T cells depends on retroviral transduction.With the advent of gene editing, insertion of a CD19-CAR into the T cell receptor (TCR) alpha constant (TRAC) locus using adeno-associated